Bolt Biotherapeutics Inc (BOLT) Actualités

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

-- Targeting Unmet Needs for Treating Solid Tumors-- REDWOOD CITY, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with...

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies...

Form 8-K - Current report

Bolt Biotherapeutics Announces Changes to its Board of Directors

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a...

Bolt Biotherapeutics to Participate in Upcoming September Conferences

REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

BOLT SHAREHOLDER ALERT: Edelson Lechtzin LLP Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shareholders to Consult Legal Counsel About the Pending Securities Fraud Class Action

BOLT SHAREHOLDER ALERT: Edelson Lechtzin LLP Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shareholders to...